Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers

PURPOSE: Mutations in the RAS/RAF/MEK/ERK signaling pathway are commonly found in biliary tract cancer (BTC). Binimetinib, a selective inhibitor of MEK1/2, has single-agent activity. Preclinical data support binimetinib combination with chemotherapy, when given in an interrupted dosing schedule. PAT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Lowery, Maeve A., Bradley, Mikaela, Chou, Joanne F., Capanu, Marinela, Gerst, Scott, Harding, James J., Dika, Imane El, Berger, Michael, Zehir, Ahmet, Ptashkin, Ryan, Wong, Philip, Rasalan-Ho, Teresa, Yu, Kenneth H., Cercek, Andrea, Morgono, Ezra, Salehi, Erica, Valentino, Emily, Hollywood, Ellen, O’Reilly, Eileen M., Abou-Alfa, Ghassan K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6615467/
https://ncbi.nlm.nih.gov/pubmed/30563938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1927
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados